Michelle Gilson
Stock Analyst at Morgan Stanley
(0.75)
# 3,003
Out of 4,496 analysts
13
Total ratings
33.33%
Success rate
-5.19%
Average return
Main Sectors:
Top Industries:
7 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Maintains: Equal-Weight | $12 → $15 | $10.03 | +49.55% | 3 | Jun 6, 2024 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $33.88 | -11.45% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | n/a | $4.52 | - | 1 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | n/a | $135.21 | - | 2 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | n/a | $9.80 | - | 1 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | n/a | $13.58 | - | 1 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | n/a | $84.09 | - | 4 | Aug 20, 2020 |
Vir Biotechnology
Jun 6, 2024
Maintains: Equal-Weight
Price Target: $12 → $15
Current: $10.03
Upside: +49.55%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $33.88
Upside: -11.45%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: n/a
Current: $4.52
Upside: -
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: n/a
Current: $135.21
Upside: -
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: n/a
Current: $9.80
Upside: -
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: n/a
Current: $13.58
Upside: -
BioMarin Pharmaceutical
Aug 20, 2020
Maintains: Buy
Price Target: n/a
Current: $84.09
Upside: -